Two‐Hour CGRP Infusion Causes Gastrointestinal Hyperactivity: Possible Relevance for CGRP Antibody Treatment

Sumatriptan Does Not Antagonize CGRP‐Induced Symptoms in Healthy Volunteers

(2020) Katrine Falkenberg et al.   HEADACHE

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

(2019) Messoud Ashina et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Cilostazol induced migraine does not respond to sumatriptan in a double blind trial

(2018) Katrine Falkenberg et al.   JOURNAL OF HEADACHE AND PAIN

Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers

(2018) Katrine Falkenberg et al.   JOURNAL OF HEADACHE AND PAIN

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

(2018) Uwe Reuter et al.   LANCET

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Anti-CGRP antibodies block CGRP-induced diarrhea in mice

(2017) Eric A. Kaiser et al.   NEUROPEPTIDES

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine

(2016) Song Guo et al.   CEPHALALGIA

Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine

(2016) Song Guo et al.   PAIN

Toward a pragmatic migraine model for drug testing: 1. Cilostazol in healthy volunteers

(2015) Emma Katrine Hansen et al.   CEPHALALGIA

Incretins and Amylin: Neuroendocrine Communication Between the Gut, Pancreas, and Brain in Control of Food Intake and Blood Glucose

(2014) Matthew R. Hayes et al.   Annual Review of Nutrition

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

(2014) David W Dodick et al.   LANCET NEUROLOGY

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

(2014) David W Dodick et al.   LANCET NEUROLOGY

Serum Levels of Calcitonin Gene-Related Peptide and Substance P are Decreased in Patients with Diabetes Mellitus and Coronary Artery Disease

(2013) LH Wang et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Localization of calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) in human gastrointestinal tract

(2012) Graeme S. Cottrell et al.   PEPTIDES

Evidence for a vascular factor in migraine

(2010) Mohammad S. Asghar et al.   ANNALS OF NEUROLOGY

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

(2010) Jakob Møller Hansen et al.   CEPHALALGIA